ALG-000184, Publications Association of Baseline Characteristics and Plasma ALG-001075 to HBsAg Responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment
ALG-000184, Publications ALG-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian HBeAg-Negative CHB Subjects
ALG-000184, Publications ALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB
ALG-000184, Publications ALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB
ALG-000184, Publications Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg
ALG-000184, Publications Preclinical Resistance Profile and Antiviral Activity of the Best-in-Class CAM-E ALG-001075, the Parent Compound of ALG-000184
ALG-000184, Publications Prolonged (>24 Week) Dosing with the Oral CAM-E Compound ALG-000184 Results In Multi-log Reductions In Hepatitis B Surface Antigen, HBV DNA, And HBV RNA Levels In Untreated E Antigen Postive Subjects With Chronic Hepatitis B
ALG-000184, Publications CAM-E ALG-000184, Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B
ALG-000184, Publications Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB)
ALG-000184, Publications ALG-000184, an Orally Administered Capsid Assembly Modulator (CAM) Reduces HBsAg in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)